Daxxity in the New York Stock Exchange for its initial public offer on June 24, 2021.
Source: NYSE
Duration It is immersing itself more deeply in artificial intelligence, announcing on Thursday the acquisition of Startup Pathway Medical for $ 63 million.
Pathway has created a clinical reference tool that doctors can use to ask questions about guidelines, medications and trials. Pathway responses are synthesized from medical literature, and Daxxity said the Montreal -based startup has one of the largest structured data sets in medicine.
The Daxxity platform, which for years was described as LinkedIn for doctors, helps doctors to keep up with medical news, administer paperwork, find references and carry out telesalud appointments with patients. Through his acquisition of Pathway, Daxxity expects doctors to also resort to the platform to answer their clinical questions.
“We hunt high and low, and I think we found the best company in the space to answer doctors' questions using AI, and was not in Silicon Valley,” said Jeff Tangney, co -founder and CEO of Daxxity, to CNBC in an interview.
The agreement closed at the end of July for a cash consideration of $ 26 million and up to $ 37 million in additional capital grants, said Daxxity.
The integration of Dxxxy with the road is underway, said Tangney, and companies are testing a product combined with thousands of doctors.
Meanwhile, patients are spinning more regularly to AI and chatbots tools to obtain answers to health -related questions, a trend that has potentially problematic consequences due to the probability of inaccurate recommendations.
During a live broadcast on Thursday where Openai announced its new GPT-5 model, CEO Sam Altman said that health consultations are one of the most important categories of chatgpt use, according to a publication on X, and added that the new model is “much better” in that area.
Daxxity already has a free AI product, Daxxity GPT, which doctors can use to generate insurance letters and summarize the graphics and reports of patients. Pathway will bring an additional “robustness.”
“What via it contributes to this party or this marriage is that they have a very solid background data set that links the doses of the guidelines to the literature to the appointments,” Phull told CNBC in an interview.
The Pathway model obtained 96% at the reference point for the US medical licenses exam.
Daxxity, which was made public in 2021, has seen that its shares amount to 10% this year after increasing 90% in 2024. The company has a market capitalization of approximately $ 11 billion.
Daxxity's shares increased approximately 6% in extended operations on Thursday after the company reported fiscal results in the first quarter that exceeded estimates. Income increased by 15% compared to the year prior to $ 145.9 million, while analysts expected sales of $ 139.5 million, according to LSE. The earnings per share of 36 cents exceeded the average estimate of 30 cents.
